Literature DB >> 28249266

Role of the Intestinal Microbiome in Cholestatic Liver Disease.

Nicholas F LaRusso1, James H Tabibian, Steven P O'Hara.   

Abstract

Hepatobiliary health and disease is influenced by multiple factors including genetics, epigenetics, and the environment. Recently, multiple lines of evidence suggest that the microbiome also plays a central role in the initiation and/or progression of several liver diseases. Our current understanding of the dynamic interplay between microbes, microbial products and liver health and pathophysiology is incomplete. However, exciting insights are continually being made that support both a central role of the microbiome and a need for further interrogation of the microbes or microbe-associated molecules involved in the initiation and progression of select liver diseases.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2017        PMID: 28249266      PMCID: PMC5941303          DOI: 10.1159/000450906

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  9 in total

1.  Primary sclerosing cholangitis: the gut-liver axis.

Authors:  James H Tabibian; Steven P O'Hara; Nicholas F Larusso
Journal:  Clin Gastroenterol Hepatol       Date:  2012-02-15       Impact factor: 11.382

2.  Could gut microbiota protect against sclerosing cholangitis?

Authors:  Hanns-Ulrich Marschall; Fredrik Bäckhed
Journal:  Hepatology       Date:  2015-11-17       Impact factor: 17.425

3.  Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.

Authors:  James H Tabibian; Steven P O'Hara; Christy E Trussoni; Pamela S Tietz; Patrick L Splinter; Taofic Mounajjed; Lee R Hagey; Nicholas F LaRusso
Journal:  Hepatology       Date:  2015-08-10       Impact factor: 17.425

4.  Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappaB.

Authors:  Xian-Ming Chen; Steven P O'Hara; Jeremy B Nelson; Patrick L Splinter; Aaron J Small; Pamela S Tietz; Andrew H Limper; Nicholas F LaRusso
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

5.  Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis.

Authors:  James H Tabibian; Steven P O'Hara; Patrick L Splinter; Christy E Trussoni; Nicholas F LaRusso
Journal:  Hepatology       Date:  2014-04-25       Impact factor: 17.425

6.  Bile duct bacterial isolates in primary sclerosing cholangitis and certain other forms of cholestasis--a study of bile cultures from ERCP.

Authors:  E S Björnsson; A F Kilander; R G Olsson
Journal:  Hepatogastroenterology       Date:  2000 Nov-Dec

7.  Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis.

Authors:  Tobias Mueller; Claudia Beutler; Almudena Hurtado Picó; Oren Shibolet; Daniel S Pratt; Andreas Pascher; Peter Neuhaus; Bertram Wiedenmann; Thomas Berg; Daniel K Podolsky
Journal:  Liver Int       Date:  2011-09-15       Impact factor: 5.828

Review 8.  Primary Sclerosing Cholangitis.

Authors:  Konstantinos N Lazaridis; Nicholas F LaRusso
Journal:  N Engl J Med       Date:  2016-09-22       Impact factor: 91.245

Review 9.  The dynamic biliary epithelia: molecules, pathways, and disease.

Authors:  Steven P O'Hara; James H Tabibian; Patrick L Splinter; Nicholas F LaRusso
Journal:  J Hepatol       Date:  2012-10-17       Impact factor: 25.083

  9 in total
  4 in total

1.  Probiotic Lactobacillus rhamnosus GG prevents progesterone metabolite epiallaopregnanolone sulfate-induced hepatic bile acid accumulation and liver injury.

Authors:  Li Ren; Qing Song; Yunhuan Liu; Lihua Zhang; Zhiming Hao; Wenke Feng
Journal:  Biochem Biophys Res Commun       Date:  2019-09-28       Impact factor: 3.575

2.  Maternal obesogenic diet enhances cholestatic liver disease in offspring.

Authors:  Michael D Thompson; Holly Hinrichs; Austin Faerber; Phillip I Tarr; Nicholas O Davidson
Journal:  J Lipid Res       Date:  2022-03-25       Impact factor: 6.676

3.  Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist.

Authors:  Adnan Malik; Ani A Kardashian; Kais Zakharia; Christopher L Bowlus; James H Tabibian
Journal:  Liver Res       Date:  2019-05-27

Review 4.  The Gut-Liver Axis in Cholestatic Liver Diseases.

Authors:  Andreas Blesl; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2021-03-21       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.